Orexo AB GAAP EPS of -SEK 0.37, revenue of SEK 157.7M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Echtzeit-Aktienkurs Orexo AB
Bid:
Ask:
Nachrichten zur Orexo AB Aktie
Orexo Q2 2023 Interim Report
UPPSALA, Sweden, July 18, 2023 /PRNewswire/ -- The patent win critical enabler for future growth Q2 2023 highlights › Total…
Orexo Q2 2023 Interim Report
The patent win critical enabler for future growth
Q2 2023 highlights
› Total net revenues of SEK 157.7 m (147.8)
› …
Invitation to presentation of Orexo’s Q2 2023 Interim Report
Uppsala, Sweden – July 7, 2023 – As previously communicated Orexo will announce the Interim Report for the second quarter…
Orexo Wins Patent Dispute Against Sun Pharma In U.S.
NEW DELHI (dpa-AFX) - Orexo AB (ORXOY) said that the US District Court for the District of New Jersey ruled…
Orexo wins patent litigation for ZUBSOLV® in the US
· The court found Orexo´s patents valid and infringed by Sun
· The outcome once again confirms the strength…
OX640: Shaping the future of nasal powder epinephrine using the innovative amorphOX platform
Orexo is breaking new ground in the area of anaphylaxis with OX640, an innovative nasal powder epinephrine product. In this…
Orexo Interim Report Q1 2023
UPPSALA, Sweden, April 27, 2023 /PRNewswire/ -- Focusing operations on Orexo´s strengths Q1 2023 highlights Total net revenues of SEK…
Orexo Interim Report Q1 2023
Focusing operations on Orexo´s strengths
Q1 2023 highlights
· Total net revenues of SEK 158.8 m (159.4)
· EBITDA of…
Invitation to presentation of Orexo’s Q1 Interim Report
Uppsala, Sweden – April 20, 2023 – As previously communicated Orexo will announce the Interim Report for the first quarter…
Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124
Uppsala, Sweden – April 3, 2023 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the expected US launch of OX124,…
Orexo publishes the Annual and Sustainability Report for 2022
UPPSALA, Sweden, March 28, 2023 /PRNewswire/ -- Orexos Annual and Sustainability Report for 2022 has been published and can be…
Orexo publishes the Annual and Sustainability Report for 2022
Uppsala, Sweden - March 28, 2023 – Orexos Annual and Sustainability Report for 2022 has been published and can be…
Orexo postpones publication of the Annual Report
UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the…
Orexo postpones publication of the Annual Report
Uppsala, Sweden – March 15, 2023 – Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual…
Notice of Annual General Meeting of Orexo
UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are…
Notice of Annual General Meeting of Orexo
The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to…
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
OX124 is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl Nine out of ten…
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
· OX124 is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl
· Nine out…
Orexo AB GAAP EPS of -SEK2.67, revenue of SEK156.1M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Orexo Interim Report Q4 2022, incl. Full Year Report
UPPSALA, Sweden, Jan. 26, 2023 /PRNewswire/ -- Important steps forward in a challenging environment Q4 2022 highlights Total net revenues…
Orexo Interim Report Q4 2022, incl. Full Year Report
Important steps forward in a challenging environment
Q4 2022 highlights
· Total net revenues of SEK 156.1 m (144.0)
·…
Orexo initiates exploratory feasibility studies of amorphOX® with two leading biopharmaceutical and vaccine companies
Orexo has successfully formulated Covid-19 spike protein in the proprietary drug delivery platform amorphOX®, showing excellent protein stability Orexo has…
Orexo initiates exploratory feasibility studies of amorphOX[®] with two leading biopharmaceutical and vaccine companies
· Orexo has successfully formulated Covid-19 spike protein in the proprietary drug delivery platform amorphOX®, showing excellent protein stability
…